Interchangeability between Pneumococcal Conjugate Vaccines: A Systematic Review and Meta-Analysis

Area of Science:

• Pediatric Vaccinology
• Health Economics
• Immunology

Background:

• Pneumococcal conjugate vaccines (PCVs) are crucial for preventing pneumococcal diseases in children.
• Assessing the interchangeability and comparative effectiveness of different PCVs is essential for public health policy.
• Existing research often lacks direct comparisons of PCV interchangeability.

Purpose of the Study:

• To evaluate the efficacy, cost-effectiveness, immunogenicity, and safety of pneumococcal conjugate vaccines (PCVs) and vaccination schedules.
• To analyze the interchangeability of PCVs in pediatric populations.
• To compare different PCV formulations regarding health outcomes and economic impact.

Main Methods:

• Systematic literature searches were conducted across multiple databases (MEDLINE, EMBASE, LILACS, Cochrane) up to April 2015.
• Included randomized controlled trials, economic evaluations, and systematic reviews assessing PCV interchangeability.
• Risk of bias was assessed using established checklists; data extraction and quality assessment were performed independently by two reviewers.

Main Results:

• No direct comparative data on PCV interchangeability was found.
• PCV10 and PCV7 demonstrated similar immunogenicity and safety when co-administered with routine pediatric vaccines.
• PCV10 and PCV13 were consistently more cost-effective than PCV7.

Conclusions:

• While direct interchangeability data is absent, PCVs exhibit comparable immunogenicity and safety profiles.
• The cost-effectiveness of PCV10 versus PCV13 depends on pricing, indirect effects, and costs.
• PCV10 excels in preventing common, less severe events like otitis media, while PCV13 is more effective against less frequent, severe invasive diseases.